FDA APPROVES INNOVIVE'S IND FOR CANCER DRUG

Innovive Pharmaceuticals has announced today that the FDA has approved its investigational new drug application, allowing the company to enter Phase I clinical trials with INNO-105 to treat adult patients with advanced solid malignancies. INNO-105 is a naturally occurring peptide that has recently demonstrated antitumor activity in a Phase I pancreatic cancer study.

INNO-105 inhibits cell growth and division by interacting with OGFr, a unique receptor found on the nuclear membrane of a wide range of malignant cells. Preclinical studies have demonstrated antitumor activity in numerous tumor types. Innovive expects to begin the clinical trial in the fourth quarter of 2005.